S. Zhuang

发表

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

J. Tabernero, L. Dirix, R. Knoblauch, 2011, Clinical Cancer Research.

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

L. Binderup, K. Burnstein, G. Schwartz, 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

S. Zhuang, F. Clow, Steven Sun, 2015, Annals of the New York Academy of Sciences.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P. Sonneveld, M. Béné, M. Vekemans, 2019, The Lancet.

Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.

K. Burnstein, S. Zhuang, 1998, Endocrinology.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors.

J. Baselga, J. Tabernero, L. Dirix, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

M. Beksac, M. Dimopoulos, Kihyun Kim, 2021, The New England journal of medicine.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

T. Fojo, S. Bates, A. Rutt, 2005, Cancer.

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

P. Sonneveld, A. Nagler, R. Hájek, 2008, Clinical lymphoma & myeloma.

Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Michael L. Wang, G. Lenz, M. Dreyling, 2014 .

Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.

J. Grem, G. Leonard, S. Zhuang, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

P. Sonneveld, A. Nagler, R. Hájek, 2007 .

Oophorectomy in carriers of BRCA mutations [3]

T. Rebbeck, B. Weber, K. Offit, 2002 .

Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.

K. Burnstein, S. Zhuang, 1998, Endocrinology.

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)

Saijuan Chen, Jianda Hu, J. Mi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival: A Gold Standard in Search of a Surrogate: The Value of Progression-Free Survival and Time to Progression as End Points of Drug Efficacy

Y. Elsayed, S. Zhuang, L. Xiu, 2009, Cancer journal.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

L. Staudt, W. Wilson, L. Sehn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010, Clinical Cancer Research.

A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer.

W. Linehan, T. Fojo, S. Bates, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSC 710428 ) , an Epothilone B Analog , in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010 .

Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines

K. Burnstein, G. Schwartz, S. Zhuang, 1997, Molecular and Cellular Endocrinology.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

P. Sonneveld, A. Nagler, R. Hájek, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

P. Sonneveld, R. Favis, R. Orlowski, 2010, Annals of Hematology.

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II

Liang Xiu, N. Bogdanova, J. Sparano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.

M. Hallek, A. Chanan-Khan, A. Howes, 2015, Future oncology.

Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy

Michael L. Wang, R. Advani, A. Goy, 2014 .

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)

P. Sonneveld, A. Nagler, R. Hájek, 2007 .

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

W. Linehan, T. Fojo, S. Bates, 2007, Clinical Cancer Research.

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

J. Laubach, V. Carlton, T. Plesner, 2016 .

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

L. Staudt, W. Wilson, R. Gascoyne, 2014 .

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

P. Sonneveld, A. Nagler, R. Hájek, 2008, Cancer.

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

P. Sonneveld, A. Nagler, R. Hájek, 2011, Clinical lymphoma, myeloma & leukemia.

Prostate cancer metastatic to skin.

W. Dahut, G. Leonard, S. Zhuang, 2003, Urology.

Relationship of Anthracycline-Free Interval to Outcomes in a Phase 3 Trial of Pegylated Liposomal Doxorubicin Plus Docetaxel Compared with Docetaxel Monotherapy in Patients with Advanced Breast Cancer Treated with Adjuvant Anthracycline.

J. Sparano, A. Londhe, S. Zhuang, 2009 .

A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).

L. Gordon, M. Dreyling, O. Hermine, 2013 .